|
C14ORF101 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.99000000103922E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.9789999999853E-06 |
| Normal-vs-Stage2 |
6.07779999999281E-05 |
| Normal-vs-Stage3 |
9.93340000254861E-08 |
| Normal-vs-Stage4 |
3.65369999999476E-06 |
| Stage1-vs-Stage2 |
4.254000E-01 |
| Stage1-vs-Stage3 |
7.019700E-02 |
| Stage1-vs-Stage4 |
1.664600E-01 |
| Stage2-vs-Stage3 |
6.292800E-01 |
| Stage2-vs-Stage4 |
6.710000E-01 |
| Stage3-vs-Stage4 |
9.933600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.81959999792747E-08 |
| Normal-vs-AfricanAmerican |
4.322900E-03 |
| Normal-vs-Asian |
2.298600E-03 |
| Caucasian-vs-AfricanAmerican |
7.261200E-01 |
| Caucasian-vs-Asian |
1.046560E-01 |
| AfricanAmerican-vs-Asian |
5.098400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.20239999999539E-05 |
| Normal-vs-Female |
5.07809999605868E-08 |
| Male-vs-Female |
4.063000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.84190000002338E-06 |
| Normal-vs-Age(41-60Yrs) |
1.99439999959417E-07 |
| Normal-vs-Age(61-80Yrs) |
1.38709999997211E-06 |
| Normal-vs-Age(81-100Yrs) |
3.564700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.423440E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.347000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.699200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.394400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.940000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.036400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.01959999999168E-05 |
| Classical-VS-Follicular |
2.526300E-02 |
| Classical-VS-Other |
9.230800E-01 |
| Classical-VS-Normal |
1.88774999999586E-05 |
| Tall-VS-Follicular |
9.046400E-02 |
| Tall-VS-Other |
2.749200E-01 |
| Tall-VS-Normal |
9.77970038285036E-10 |
| Follicular-VS-Other |
5.368400E-01 |
| Follicular-VS-Normal |
2.17859999995795E-06 |
| Other-VS-Normal |
1.098360E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.74699999974959E-07 |
| Normal-vs-N1 |
3.025800E-04 |
| N0-vs-N1 |
5.450600E-01 |
|
|
